1. In Vivo

Philips Puts Its Money On Electrical Geodesics – The Universal Brain Flashlight

 
• By Ashley Yeo

The new-found interest in – and diagnostic and therapeutic potential of – EEG was described to In Vivo by Electrical Geodesics co-founder Ann Bunnenberg during the 2017 GMTCC in May. Not two months later, Philips had made the Oregon company another of its 2017 M&A conquests.

In paying £29 million ($37 million) to acquire Electrical Geodesics Inc., the Eugene, OR-based developer of non-invasive technologies for monitoring brain activity, Philips Healthcare has bought a relatively small company ($14.3 million sales in 2016) that significantly extends its reach in neurological disorders such as stroke, epilepsy, traumatic brain injury and Parkinson’s disease. [See Deal]

The deal was signed on June 22, and like the one for Spectranetics, was slated to close in the third...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.